Overview

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Evidence regarding optimal methods of insulin dose adjustment is lacking in the literature. The purpose of this study is to evaluate the efficacy and safety of two approaches to escalate prandial insulin therapy in participants with type 2 diabetes mellitus not achieving adequate glycemic control on basal insulin.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin
Insulin Glargine
Insulin Lispro
Insulin, Globin Zinc